News und Analysen
Discover Financial Services Announces Fourth Quarter 2024 Earnings Release on January 22, 2025, and Conference Call on January 23, 2025
Discover Financial Services (NYSE: DFS) plans to report its Fourth quarter 2024 results after the market closes on Wednesday, January 22, 2025. The earnings release will be available through
Equity Bancshares, Inc. Will Announce Fourth Quarter 2024 Results on January 22, 2025
Equity Bancshares, Inc. (NYSE:EQBK), (“Equity”), the Wichita-based holding company of Equity Bank, will release its fourth quarter results on Wednesday, January 22, 2025, with a press release
Martin Midstream Partners L.P. Announces Termination of Merger Agreement and Cancellation of Special Meeting
Martin Midstream Partners L.P. (“MMLP”) (Nasdaq: MMLP) today announced the termination of the previously announced Agreement and Plan of Merger (the “Merger Agreement”), dated October 3, 2024, with
Form 8.3 - The Vanguard Group, Inc.: Aviva plc
Redfin Reports U.S. Home Prices Rose 0.5% in November
(NASDAQ: RDFN) — U.S. home prices grew 0.5% from a month earlier in November on a seasonally adjusted basis, the third consecutive month with a 0.5% increase. That’s according to a new report from
Form 8.3 - The Vanguard Group, Inc.: Aviva plc
Form 8.3 - The Vanguard Group, Inc.: Hargreaves Lansdown plc
Savara Announces New Employment Inducement Grant
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to five new employees.
On December 20
Bankwell Financial Group Director, Lawrence B. Seidman, Approved to Increase Position in Company
Bankwell Financial Group, Inc. (NASDAQ: BWFG), the parent company of Bankwell Bank, has announced board approval of a measure that will allow individual shareholder and director, Lawrence B
EQS-News: Abivax Announces a Change to the Composition of its Board of Directors
EQS-News: HelloFresh SE announces further up to EUR 75 million share buy-back
Puma Biotechnology’s NERLYNX® Included in NCCN Clinical Practice Guidelines for the Treatment of Cervical Cancer with a HER2 Mutation
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for
Redfin Reports Home Sales Surge by Double Digits in Pricey West Coast Markets
(NASDAQ: RDFN) — In Portland, OR, home sales jumped 27.6% year over year in November—the biggest increase among the 50 most populous U.S. metropolitan areas, according to a new report from Redfin (
Form 8.3 - The Vanguard Group, Inc.: Aviva plc
Form 8.3 - The Vanguard Group, Inc.: Hargreaves Lansdown plc
Trane Technologies Named to S&P Dow Jones Sustainability World and North America Indices
Trane Technologies (NYSE:TT), a global climate innovator, has been named to the S&P Dow Jones Sustainability World Index for the fourth consecutive year and the North America Index for the
ICON and Its Employees Celebrated for Excellence in the Field of Clinical Research
ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, has been honoured with numerous awards in the second half of 2024.
On TIME Magazine’s 2024
Granite REIT Notice of Conference Call for Fourth Quarter and Year-End 2024 Results
Granite Real Estate Investment Trust (“Granite”) (TSX: GRT.UN / NYSE: GRP.U) expects to announce its financial results for the fourth quarter and year ended December 31, 2024 after the close of
Mettler-Toledo International Inc. to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Mettler-Toledo International Inc. (NYSE: MTD) today announced it will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Tuesday, January 14, 2025 at 3:45 p.m
U.S. FDA Approves Pfizer’s BRAFTOVI® Combination Regimen as First-Line Treatment of BRAF V600E-Mutant Metastatic Colorectal Cancer
Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as ERBITUX®) and mFOLFOX6
U.S. FDA Approves Pfizer’s BRAFTOVI® Combination Regimen as First-Line Treatment of BRAF V600E-Mutant Metastatic Colorectal Cancer
Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as ERBITUX®) and mFOLFOX6
Pent-up Demand Fuels U.S. Public Sector Cloud Boom
The U.S. public sector is quickly adopting public cloud services, beginning a long-awaited transition from legacy systems to advanced multicloud platforms, according to a new research report
Interactive Brokers verbessert die webbasierte Handelserfahrung für Finanzberater weltweit
Interactive Brokers (Nasdaq: IBKR, ein automatisierter globaler elektronischer Broker, hat sein webbasiertes Advisor Portal erheblich verbessert und bietet Finanzberatern weltweit fortschrittliche
EQS-News: Knorr-Bremse divests R.H. Sheppard Co., Inc. in North America and writes down remaining purchase price receivable




